HeartBeam Prices $10 Million Public Offering of Common Stock
HeartBeam, Inc., a medical technology company dedicated to advancing cardiac care through innovative diagnostic solutions, has announced the pricing of its underwritten public offering of common stock, marking a significant step in its growth and commercialization strategy. The company revealed that it will offer 12,500,000 shares of its common stock, generating gross proceeds of approximately $10 million before accounting for underwriting discounts, commissions, and other associated expenses.
This latest financing initiative reflects growing confidence in HeartBeam’s vision and technology, particularly as the company moves closer to broader commercialization of its products. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions, which include standard regulatory approvals and the satisfaction of other procedural requirements.
In addition to the base offering, HeartBeam has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock. This option, often referred to as an over-allotment option or “greenshoe,” provides flexibility to meet potential excess demand in the market. Should the underwriters choose to exercise this option in full, the total size of the offering could increase meaningfully, further strengthening the company’s capital position.
One of the most notable aspects of this offering is the strong participation from key stakeholders. The financing is being led by ClearCardio™, HeartBeam’s first commercial customer, alongside the company’s executive leadership team, board members, existing investors, and several institutional investors with a long-term, fundamentals-driven approach. This level of insider and strategic investor participation is often viewed as a strong vote of confidence in a company’s technology, business model, and future prospects.
ClearCardio’s involvement is particularly significant. As HeartBeam’s first commercial customer, its decision to participate as an investor highlights both validation of the company’s technology and alignment of strategic interests. This dual role strengthens the partnership between the two organizations and underscores the real-world applicability of HeartBeam’s solutions in clinical and preventive care settings.
HeartBeam plans to allocate the net proceeds from this offering toward several key initiatives that are central to its long-term growth strategy. A primary focus will be the continued commercialization of its FDA-cleared 12-lead synthesized electrocardiogram (ECG) system. This technology is designed to provide high-quality cardiac data in a more accessible and user-friendly format, enabling improved monitoring and earlier detection of cardiac conditions.
In addition to commercialization efforts, the company will invest in advancing the development of its extended-wear cardiac monitoring patch. This next-generation device is intended to provide continuous, long-duration monitoring, offering clinicians deeper insights into a patient’s cardiac health over time. Such innovations are particularly valuable in detecting intermittent or hard-to-capture cardiac events that may not appear during short-term monitoring.
Another major area of investment will be HeartBeam’s heart attack detection initiatives. By leveraging its proprietary technologies and data-driven approaches, the company aims to improve the speed and accuracy of identifying acute cardiac events. Early detection is critical in cardiac care, as it can significantly impact patient outcomes by enabling faster intervention and treatment.
Artificial intelligence (AI) also plays a central role in HeartBeam’s roadmap. The company intends to further enhance its AI capabilities, which are integrated into its cardiac monitoring platform. By applying advanced algorithms to ECG data, HeartBeam seeks to deliver more actionable insights to both patients and healthcare providers. These AI-driven insights can help identify patterns, predict potential issues, and support more informed clinical decision-making.
Beyond these targeted investments, a portion of the proceeds will be used for working capital and general corporate purposes. This includes supporting day-to-day operations, scaling infrastructure, and maintaining the flexibility needed to respond to market opportunities as they arise.
Commenting on the offering, Robert Eno, Chief Executive Officer of HeartBeam, emphasized the strategic importance of this financing. He noted that the capital raised will enable the company to execute on its key initiatives and expand the reach of its cardiac monitoring platform. Eno also highlighted the importance of ClearCardio’s participation, describing it as a meaningful validation of HeartBeam’s technology and its relevance in high-engagement preventive cardiology and concierge healthcare markets.
According to Eno, the involvement of a commercial customer as an investor not only reinforces confidence in the company’s solutions but also signals growing demand for more accessible and actionable cardiac insights. As healthcare continues to shift toward preventive and personalized care models, technologies that enable early detection and continuous monitoring are becoming increasingly important.
The offering is being managed by Titan Partners, a division of American Capital Partners, which is serving as the sole bookrunner. As the bookrunner, Titan Partners is responsible for coordinating the offering, managing investor interest, and facilitating the distribution of shares.
From a regulatory standpoint, the offering is being conducted pursuant to a shelf registration statement on Form S-3/A that was previously filed with the U.S. Securities and Exchange Commission (SEC) on March 13, 2026, and declared effective on March 17, 2026. This type of registration allows the company to offer securities in one or more tranches over time, providing flexibility in accessing capital markets when conditions are favorable.
A preliminary prospectus supplement, along with the accompanying prospectus, has already been filed with the SEC and is available to the public through its website. These documents provide detailed information about the offering, including the terms, risk factors, and intended use of proceeds. A final prospectus supplement will also be filed following the completion of the pricing process.
Investors interested in obtaining copies of the final prospectus supplement and related materials will be able to do so through Titan Partners Group LLC. The firm has provided multiple channels for access, including phone and email, ensuring transparency and accessibility for potential investors.
It is important to note that this announcement does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such actions would be unlawful. The sale of these securities is subject to compliance with applicable registration and qualification requirements under state and federal securities laws.
Overall, this public offering represents a significant milestone for HeartBeam as it continues to advance its mission of transforming cardiac care. With strong backing from strategic partners, leadership, and institutional investors, the company is well-positioned to accelerate its commercialization efforts, expand its technological capabilities, and deliver innovative solutions that address critical needs in cardiovascular health.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement.
